ProShare Advisors
ABEO icon

ProShare Advisors’s Abeona Therapeutics ABEO Stock Holding History

ProShare Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-645
Closed -$30K – 2368
2021
Q1 		$30K Buy
645
+110
+21% +$6.06K ﹤0.01% 2253
2020
Q4 		$21K Buy
+535
New +$18.2K ﹤0.01% 2086

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

ProShare Advisors's ABEO Position: Q2 2021 in Review

ProShare Advisors sold out of Abeona Therapeutics (ABEO) in Q2 2021, closing a stake of 645 shares — an estimated $30K sold.

ProShare Advisors first reported a position in ABEO in Q4 2020 and held it in 2 quarters. The position peaked at $30K in Q1 2021. 70 funds tracked by Wall St. Rank hold ABEO as of Q2 2021.

  • ProShare Advisors reported no remaining Abeona Therapeutics position as of Q2 2021 after selling out during the quarter.
  • ProShare Advisors sold 645 Abeona Therapeutics shares in Q2 2021, an estimated $30K.
  • ProShare Advisors first reported a position in Abeona Therapeutics in Q4 2020 and held it in 2 quarters.
  • ProShare Advisors's Abeona Therapeutics position peaked at $30K in Q1 2021.
  • 70 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2021.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.